• Publications
  • Influence
Comparison of MART‐1 Frozen Sections to Permanent Sections Using a Rapid 19‐Minute Protocol
Frozen sections stained with MART‐1 provide information equivalent to that obtained from M ART‐1 stained permanent sections, and Mohs surgeons using Mart‐1 can feel confident that they have the same information as they would have obtained using permanent sections using the slow Mohs method. Expand
Rapid Frozen Section Immunostaining of Melanocytes by Microphthalmia-Associated Transcription Factor
The experience with MITF IHC indicates that it is a dependable immunostain in frozen sections, and may prove to be useful in MMS as an adjunct to hematoxylin and eosin and MART-1 IHC for interpretation of margins for melanoma in situ on CSDS. Expand
Immunohistochemical Stains in Mohs Surgery: A Review
This article reviews immunohistochemical stains that have been employed in Mohs micrographic surgery and evaluates their utility in enhancing detection of residual tumors with respect to tumor type, particularly in situations in which detection of remaining tumor cells may be difficult. Expand
Mohs surgery for melanoma in situ: how we do it.
The authors describe their technique for treating melanoma in situ with Mohs surgery, which is especially useful in the management of lentigo maligna, which often has indistinct clinical margins. Expand
CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma
Glioma invasion into the CNS involves the interaction of tumor cells with the host’s cells and extracellular matrix (ECM) molecules. In this study, the expression of ECM-associated andExpand
Modulation of hyaluronan production by CD44 positive glioma cells
Data show that CD44 specific ligands, such as the IM7 antibody or oligoHA‐10 could down‐regulate or up-regulate glioma HA production, respectively, and suggest that interference with CD44/HA may lead to the discovery and development of new treatment modalities forglioma. Expand
Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma
Abstract 728 Background: LM, an antibody-drug conjugate (ADC), is designed to specifically kill CD56+ cancer cells and contains a potent maytansinoid cytotoxic agent (DM1) attached to aExpand
Innovative 19‐Minute Rapid Cytokeratin Immunostaining of Nonmelanoma Skin Cancer in Mohs Micrographic Surgery
The 19‐minute CK immunohistochemistry protocol in frozen tissue appears to be as effective at labeling tumor cells of SCC and BCC as methods requiring permanent sections and is effective in uncovering subtle perineural invasion. Expand
A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive
The primary study objectives are to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Expand
Scoring of Mohs tissue in one-piece processing to prevent tissue crumbling or detachment from the embedding medium while sectioning.
Mohs micrographic surgery tissue-processing techniques vary widely, yet all aim to produce quality sections of tissue that allow viewing of 100% of the peripheral and deep margins in the same plane.Expand